Published

IUPHAR Article: Psilocybin induces long-lasting effects via 5-HT receptors in mouse models of chronic pain.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Pharmacological research
Date: 2025-05-01
Source: PubMed
DOI: 10.1016/j.phrs.2025.107699
PubMed: 40107634

Authors

Koseli E Buzzi B Honaker T Rakholia Y Lewis M Gaines-Smith M Jaster AM Gonzalez-Maeso J Damaj MI

Watch author

Derived topics and classifications

psilocybin Chronic Pain Receptor Pharmacology Animal Study Safety Inflammation Animal Study

Citation graph

0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine2026-05-01 IUPHAR Article: Psilocybin induces long-lasting effects via 5-HT receptors in mouse models of chronic pain.2025-05-01

Related papers

Chronic pain education: past, present, and future of psychedelics for the management of chronic painPain Medicine · 2024-12-10 Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesiaCommunications Biology · 2026-04-24 Pharmacology of Classical Psychedelic in Mouse Models of Chronic PainJournal of Pain · 2024-03-31 Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerClinicalTrials.gov · 2026-08-05 Pilot study of psilocybin in patients with post-treatment lyme diseaseScientific Reports · 2026-02-25 Ergotamine enhances circadian amplitude and diurnally mitigates nitroglycerin-induced mechanical hypersensitivity.The journal of headache and pain · 2025-05-23 Psilocybin Has No Analgesic Properties in Multiple Mouse Models of Acute and Chronic PainJournal of Pain · 2025-04-01 Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study.Headache · 2024-01-01